Importance of post-approval real-word evidence

Eur Heart J Cardiovasc Pharmacother. 2018 Jan 1;4(1):10-11. doi: 10.1093/ehjcvp/pvx035.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Adenosine / adverse effects
  • Adenosine / analogs & derivatives*
  • Adverse Drug Reaction Reporting Systems*
  • Humans
  • Purinergic P2Y Receptor Antagonists / adverse effects*
  • Ticagrelor
  • United States
  • United States Food and Drug Administration

Substances

  • Purinergic P2Y Receptor Antagonists
  • Ticagrelor
  • Adenosine